September 2021 Promotion of finasteride by Careforsons Limited t/a Sons
Published 14 December 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-september-2021/september-2021-promotion-of-finasteride-by-careforsons-limited-ta-sons
A member of the public contacted MHRA to raise concerns about the information provided for finasteride on the Sons website. The complainant did not consider that the mental-health side-effects and emotional wellbeing were sufficiently or appropriately discussed on the webpages where this prescription-only medicine was highlighted.
MHRA contacted Careforsons Limited regarding the concerns and asked them to review their website to ensure readers are given a balanced overview of the potential risks and benefits of using this medicine and to avoid absolute statements of safety. You can see details of MHRA guidance for providers that offer medicinal treatment services in Appendix 6 of the MHRA Blue Guide.